SCHEMBL3560370

SCHEMBL3560370

Clc1cc(N2CCOCC2)nc(NCc2ccncc2)n1

nearest known ligand 0.62

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
PIK3CA P42336 5/20 0.62
PIK3CB P42338 8/20 0.58
HTT P42858 3/20 0.58
PKM P14618 1/20 0.58
TSHR P16473 1/20 0.58
CRHBP P24387 1/20 0.58
CRHR2 Q13324 1/20 0.58
MAPT P10636 2/20 0.55
KDM4E B2RXH2 1/20 0.55
ALOX12 P18054 1/20 0.55
RAF1 P04049 1/20 0.53
BRAF P15056 1/20 0.53
PIK3CD O00329 1/20 0.52
CYP1A2 P05177 1/20 0.50
CYP2D6 P10635 1/20 0.50
KMT2A Q03164 1/20 0.47
NAPEPLD Q6IQ20 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13406352 0.89 PIK3CA (0.64) PIK3CAPIK3CBHTTPKMTSHR
SCHEMBL3558618 0.86 PIK3CA (0.66) PIK3CAPIK3CBHTTPKMTSHR
SCHEMBL21313535 0.82 MAPT (0.52) PIK3CAHTTMAPTRAF1BRAF
SCHEMBL3558706 0.81 PIK3CB (0.59) PIK3CAPIK3CBHTTPKMTSHR
SCHEMBL8348735 0.80 RAF1 (0.58) PIK3CBHTTPKMTSHRCRHBP
SCHEMBL3552326 0.80 PIK3CA (0.65) PIK3CAPIK3CBHTTPKMTSHR
SCHEMBL1310145 0.79 HTT (0.64) PIK3CAHTTMAPTKDM4EALOX12
SCHEMBL1029556 0.78 PIK3CA (0.67) PIK3CAPIK3CBHTTPKMTSHR
SCHEMBL12963488 0.78 RAF1 (0.56) PIK3CAPIK3CBHTTPKMTSHR
SCHEMBL16094881 0.78 RAF1 (0.62) PIK3CAPIK3CBHTTPKMTSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7696204-B2 Pharmaceutical compounds LUDWIG INSTITUTE FOR CANCER RESEARCH (CH) 2010-04-13 US disclosed
US-7696204-B2 Pharmaceutical compounds LUDWIG INSTITUTE FOR CANCER RESEARCH (CH) 2010-04-13 US disclosed
US-7696204-B2 Pharmaceutical compounds LUDWIG INSTITUTE FOR CANCER RESEARCH (CH) 2010-04-13 US disclosed
US-20090042884-A1 Pharmaceutical Compounds F.HOFFMANN-LA ROCHE AG (CH) 2009-02-12 US disclosed
US-20090042884-A1 Pharmaceutical Compounds F.HOFFMANN-LA ROCHE AG (CH) 2009-02-12 US disclosed
US-20090042884-A1 Pharmaceutical Compounds F.HOFFMANN-LA ROCHE AG (CH) 2009-02-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090042884-A1 Pharmaceutical Compounds PIK3CA, JAK1, PIK3R1 PIK3CA 1/4885PIK3CB 10/4885HTT 3735/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.